Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience

Conclusion.
At a single center, the tpCR and GBG pCR rates of dd AC followed by THP are high at 72% and 53%, respectively. The Oncologist 2017;22:139–143

Implications for Practice: This is the first study describing the role of doxorubicin and cyclophosphamide followed by paclitaxel and dual anti-HER2 therapy with trastuzumab and pertuzumab (ACTHP) in patients with early stage HER2-positive breast cancer. Total (breast + lymph node) pathological complete remission (pCR) remission (ypT0/is ypN0) and German Breast Group pCR rates (ypT0/ ypN0) were high at 72% and 53%, respectively, with the ACTHP regimen. Rate of axillary clearance in patients with known axillary involvement was high at 85%, which may translate into less extensive axillary surgeries in this subset in the future.

Source: The Oncologist - February 27, 2017 Category: Cancer & Oncology Authors: Singh, J. C., Mamtani, A., Barrio, A., Morrow, M., Sugarman, S., Jones, L. W., Yu, A. F., Argolo, D., Smyth, L. M., Modi, S., Schweber, S., Boafo, C., Patil, S., Norton, L., Baselga, J., Hudis, C. A., Dang, C. Tags: Breast Cancer Source Type: research